

AMGEN INC.

AMGEN Center  
One Amgen Center Drive  
Thousand Oaks, CA 91320  
(805) 499-5725

FAX Number: (805) 499-8011 or (805) 447-1090

DATE: July 14, 2004

TO: Initial Patent Examination's  
Filing Receipt Corrections  
Facsimile: (703) 746-9195  
Phone: (703) 308-1202

FROM: Lynne Buchsbaum on behalf of Joyce Vogel  
Phone: (805) 447-8246

There are a total of 2 pages being transmitted including this cover sheet. If all of the pages are not received, please contact us. Thank you.

Filing Receipt Corrections,

Attached is a copy of the Filing Receipt we received from the USPTO for U.S.S.N. 10/758,622. Under "Title" please replace the Title "Glial derived neurotrophic factor" with – Glial Cell Line-Derived Neurotrophic Factor – . I have also circled the incorrect information and indicated what needs to be added directly on a copy of the Filing Receipt.

Please send us a "Corrected Filing Receipt" as soon as possible.

Thank you in advance for making this correction.

Lynne Buchsbaum on behalf of Joyce Vogel  
Patent Operations Dept.

---

This transmission may contain confidential and/or privileged information intended solely for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If you have received this facsimile in error, please notify us immediately by calling (805) 447-1086.



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/758,622	01/14/2004	1653	770	S-225N	31	1	1

21069  
 AMGEN INCORPORATED  
 MAIL STOP 27-4-A  
 ONE AMGEN CENTER DRIVE  
 THOUSAND OAKS, CA 91320-1799

JUN - 8 2004

CONFIRMATION NO. 6106

## FILING RECEIPT



\*OC00000012846212\*

Date Mailed: 06/02/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

- ✓Leu-Fen H. Lin, Boulder, CO;
- ✓Franklin D. Collins, Agoura Hills, CA;
- ✓Daniel H. Doherty, Boulder, CO;
- ✓Jack Lile, Nederland, CO;
- ✓Susan Bektesh, Boulder, CO;

## Assignment For Published Patent Application

✓Amgen Inc.;

## Domestic Priority data as claimed by applicant

This application is a CON of 08/182,183 05/23/1994 ✓  
 which is a 371 of PCT/US92/07888 09/17/1992  
 which is a CIP of 07/855,413 03/19/1992 ABN ✓  
 which is a CIP of 07/788,423 11/06/1991 ABN ✓  
 which is a CIP of 07/774,109 10/08/1991 ABN ✓  
 which is a CIP of 07/764,685 09/20/1991 ABN ✓

## Foreign Applications

If Required, Foreign Filing License Granted: 06/02/2004

Projected Publication Date: 09/09/2004

Non-Publication Request: No

Early Publication Request: No

Title

Glial derived neurotrophic factor

CELL LINE-DERIVED

Preliminary Class

435

---

**LICENSE FOR FOREIGN FILING UNDER  
Title 35, United States Code, Section 184  
Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).